Prognostic value of the apoptotic index analysed jointly with selected cell cycle regulators and proliferation markers in non-small cell lung cancer

Lung Cancer

Volumn 66, Issue 1, 2009, Pages 127-133

  Dworakowska, Dorota ^a,b   Jassem, Ewa ^a   Jassem, Jacek ^a   Karmoliński, Andrzej ^c   Łapiński, Mariusz ^a   Tomaszewski, Dariusz ^a   Rzyman, Witold ^a   Jaśkiewicz, Kazimierz ^a   Sworczak, Krzysztof ^a   Grossman, Ashley B ^b  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c WHIPPS CROSS UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

AI; Cyclin D1; mdm2; NSCLC; p21WAF1 CIP1; p53; PCNA; pRb; Prognosis

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLINE; PROTEIN MDM2; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ADULT; APOPTOSIS; ARTICLE; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; NICK END LABELING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE PROTEINS; CELL PROLIFERATION; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTO-ONCOGENE PROTEINS C-MDM2; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 68949215868     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.01.008     Document Type: Article

References (38)

1. Baldini E.H., and Strauss G.M. Women and lung cancer: waiting to exhale. Chest 112 (1997) 229S-234S
2. Jassem J., Skokowski J., Dziadziuszko R., Jassem E., Szymanowska A., Rzyman W., et al. Results of surgical treatment of non-small cell lung cancer: validation of the new postoperative pathologic TNM classification. J Thorac Cardiovasc Surg 119 (2000) 1141-1146
3. Strauss G.M. Prognostic markers in resectable non-small cell lung cancer. Hematol Oncol Clin North Am 11 (1997) 409-434
4. Filipits M., Pirker R., Dunant A., Lantuejoul S., Schmid K., Huynh A., et al. Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program. J Clin Oncol 25 (2007) 2735-2740
5. Kerr J.F., Winterford C.M., and Harmon B.V. Apoptosis. Its significance in cancer and cancer therapy. Cancer 73 (1994) 2013-2026
6. Levine A.J., Momand J., and Finlay C.A. The p53 tumour suppressor gene. Nature 351 (1991) 453-456
7. Prives C., and Hall P.A. The p53 pathway. J Pathol 187 (1999) 112-126
8. Yap D.B., Hsieh J.K., Chan F.S., and Lu X. mdm2: a bridge over the two tumour suppressors, p53 and Rb. Oncogene 18 (1999) 7681-7689
9. el-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75 (1993) 817-825
10. Roninson I.B. Oncogenic functions of tumour suppressor p21(Waf1/Cip1/Sdi1): association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett 179 (2002) 1-14
11. Dworakowska D., Jassem E., Jassem J., Karmolinski A., Dworakowski R., Wirth T., et al. Clinical significance of apoptotic index in non-small cell lung cancer: correlation with p53, mdm2, pRb and p21WAF1/CIP1 protein expression. J Cancer Res Clin Oncol 131 (2005) 617-623
12. Gautschi O., Ratschiller D., Gugger M., Betticher D.C., and Heighway J. Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation. Lung Cancer 55 (2007) 1-14
13. Sobin LH, Fleming ID. TNM classification of malignant tumors, 5th ed. Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997; 80:1803-1804.
14. Dworakowska D., Jassem E., Jassem J., Boltze C., Wiedorn K.H., Dworakowski R., et al. Absence of prognostic significance of p21(WAF1/CIP1) protein expression in non-small cell lung cancer. Acta Oncol 44 (2005) 75-79
15. Dworakowska D., Jassem E., Jassem J., Boltze C., Wiedorn K.H., Dworakowski R., et al. Prognostic value of cyclin D1 overexpression in correlation with pRb and p53 status in non-small cell lung cancer (NSCLC). J Cancer Res Clin Oncol 131 (2005) 479-485
16. Dworakowska D., Gozdz S., Jassem E., Badzio A., Kobierska G., Urbaniak A., et al. Prognostic relevance of proliferating cell nuclear antigen and p53 expression in non-small cell lung cancer. Lung Cancer 35 (2002) 35-41
17. Gerl R., and Vaux D.L. Apoptosis in the development and treatment of cancer. Carcinogenesis 26 (2005) 263-270
18. Puglisi F., Minisini A.M., Aprile G., Barbone F., Cataldi P., Artico D., et al. Balance between cell division and cell death as predictor of survival in patients with non-small-cell lung cancer. Oncology 63 (2002) 76-83
19. Shivapurkar N., Reddy J., Chaudhary P.M., and Gazdar A.F. Apoptosis and lung cancer: a review. J Cell Biochem 88 (2003) 885-898
20. Tanaka F., Takata T., Yamada T., Yanagihara K., Otake Y., Miyahara R., et al. Apoptotic tumor-cell death in response to cell proliferation is influenced by p53 status in resected non-small cell lung cancer. Lung Cancer 36 (2002) 27-32
21. Tanaka F., Kawano Y., Li M., Takata T., Miyahara R., Yanagihara K., et al. Prognostic significance of apoptotic index in completely resected non-small-cell lung cancer. J Clin Oncol 17 (1999) 2728-2736
22. Sherr C.J. Cancer cell cycles. Science 274 (1996) 1672-1677
23. Tormanen U., Eerola A.K., Rainio P., Vahakangas K., Soini Y., Sormunen R., et al. Enhanced apoptosis predicts shortened survival in non-small cell lung carcinoma. Cancer Res 55 (1995) 5595-5602
24. Langendijk H., Aaronson N.K., de Jong J.M., ten Velde G.P., Muller M.J., and Wouters M. The prognostic impact of quality of life assessed with the EORTC QLQ-C30 in inoperable non-small cell lung carcinoma treated with radiotherapy. Radiother Oncol 55 (2000) 19-25
25. Macluskey M., Baillie R., Chandrachud L.M., Pendleton N., and Schor A.M. High levels of apoptosis are associated with improved survival in non-small cell lung cancer. Anticancer Res 20 (2000) 2123-2128
26. Matturri L., Colombo B., and Lavezzi A.M. Evidence for apoptosis in non-small cell lung carcinoma. Relationship with cell kinetics and prognosis. Anal Quant Cytol Histol 21 (1999) 240-244
27. Hanaoka T., Nakayama J., Haniuda M., and Sato T.A. Immunohistochemical demonstration of apoptosis-regulated proteins, Bcl-2 and Bax, in resected non-small-cell lung cancers. Int J Clin Oncol 7 (2002) 152-158
28. Tanaka F., Otake Y., Yanagihara K., Yamada T., Miyahara R., Kawano Y., et al. Apoptosis and p53 status predict the efficacy of postoperative administration of UFT in non-small cell lung cancer. Br J Cancer 84 (2001) 263-269
29. Pulkkanen K.J., Laukkanen M.O., Naarala J., and Yla-Herttuala S. False-positive apoptosis signal in mouse kidney and liver detected with TUNEL assay. Apoptosis 5 (2000) 329-333
30. Dworakowska D., Jassem E., Jassem J., Wiedorn K.H., Boltze C., Karmolinski A., et al. Prognostic relevance of altered pRb and p53 protein expression in surgically treated non-small cell lung cancer patients. Oncology 67 (2004) 60-66
31. Dworakowska D., Jassem E., Jassem J., Peters B., Dziadziuszko R., Zylicz M., et al. MDM2 gene amplification: a new independent factor of adverse prognosis in non-small cell lung cancer (NSCLC). Lung Cancer 43 (2004) 285-295
32. Brambilla E., Moro D., Gazzeri S., and Brambilla C. Alterations of expression of Rb, p16(INK4A) and cyclin D1 in non-small cell lung carcinoma and their clinical significance. J Pathol 188 (1999) 351-360
33. Marchetti A., Doglioni C., Barbareschi M., Buttitta F., Pellegrini S., Gaeta P., et al. Cyclin D1 and retinoblastoma susceptibility gene alterations in non-small cell lung cancer. Int J Cancer 75 (1998) 187-192
34. Serrano M., Hannon G.J., and Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366 (1993) 704-707
35. Muller H., Lukas J., Schneider A., Warthoe P., Bartek J., Eilers M., et al. Cyclin D1 expression is regulated by the retinoblastoma protein. Proc Natl Acad Sci USA 91 (1994) 2945-2949
36. Vonlanthen S., Heighway J., Kappeler A., Altermatt H.J., Borner M.M., and Betticher D.C. p21 is associated with cyclin D1, p16INK4a and pRb expression in resectable non-small cell lung cancer. Int J Oncol 16 (2000) 951-957
37. Lukas J., Muller H., Bartkova J., Spitkovsky D., Kjerulff A.A., Jansen-Durr P., et al. DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin D1 function in G1. J Cell Biol 125 (1994) 625-638
38. Marchetti A., Buttitta F., Pellegrini S., Merlo G., Chella A., and Angeletti C.A. Bevilacqua G. mdm2 gene amplification and overexpression in non-small cell lung carcinomas with accumulation of the p53 protein in the absence of p53 gene mutations. Diagn Mol Pathol 4 (1995) 93-97